Intec Pharma Ltd (NASDAQ:NTEC) shares, rose in value on Wednesday, 07/21/21, with the stock price up by 8.71% to the previous day’s close as strong demand from buyers drove the stock to $3.62.
Actively observing the price movement in the last trading, the stock closed the session at $3.33, falling within a range of $3.33 and $3.8599. The value of beta (5-year monthly) was 1.14. Referring to stock’s 52-week performance, its high was $15.82, and the low was $2.20. On the whole, NTEC has fluctuated by -12.14% over the past month.
As a result, investors might want to see an improvement in the stock’s price before the company announces its earnings report. Analysts are projecting the company’s earnings per share (EPS) to be -$0.64, which is expected to increase to $4.9 for fiscal year $2.99 and then to about -$2.45 by fiscal year 2022. Data indicates that the EPS growth is expected to be 173.30% in 2022, while the next year’s EPS growth is forecast to be -181.90%.
Revisions could be a useful indicator to get insight on short-term price movement; so for the company, there were no upward and no downward review(s) in last seven days. We see that NTEC’s technical picture suggests that short-term indicators denote the stock is a 50% Sell on average. However, medium term indicators have put the stock in the category of 100% Sell while long term indicators on average have been pointing out that it is a 100% Sell.
1 analyst(s) have assigned their ratings of the stock’s forecast evaluation on a scale of 1.00-5.00 to indicate a strong buy to a strong sell recommendation. The stock is rated as a Hold by 0 analyst(s), 1 recommend it as a Buy and 0 called the NTEC stock Overweight. In the meantime, 0 analyst(s) believe the stock as Underweight and 0 think it is a Sell. Thus, investors eager to increase their holdings of the company’s stock will have an opportunity to do so as the average rating for the stock is Buy.
The stock’s technical analysis shows that the PEG ratio is about 0, with the price of NTEC currently trading nearly 6.46% and -1.90% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 53.11, while the 7-day volatility ratio is showing 9.45% which for the 30-day chart, stands at 9.26%. Furthermore, Intec Pharma Ltd (NTEC)’s average true range (ATR) is 0.37. The company’s stock has been forecasted to trade at an average price of $13.00 over the course of the next 52 weeks, with a low of $13.00 and a high of $13.00. Based on these price targets, the low is -259.12% off current price, whereas the price has to move -259.12% to reach the yearly target high. Additionally, analysts’ median price of $13.00 is likely to be welcomed by investors because it represents a decrease of -259.12% from the current levels.
A comparison of Intec Pharma Ltd (NTEC) with its peers suggests the former has fared considerably weaker in the market. NTEC showed an intraday change of 8.71% in last session, and over the past year, it shrunk by -63.52%%. On the other hand, the price of Omeros Corporation (OMER) has risen 0.49% on the day. The stock, however, is off -0.62% from where it was a year ago. Other than that, the overall performance of the S&P 500 during the last trading session shows that it gained 0.82%. Meanwhile, the Dow Jones Industrial Improved by 0.83%.
Data on historical trading for Intec Pharma Ltd (NASDAQ:NTEC) indicates that the trading volumes over the past 3 months, they’ve averaged 1.36 million. According to company’s latest data on outstanding shares, there are 4.82 million shares outstanding.
Nearly 2.72% of Intec Pharma Ltd’s shares belong to company insiders and institutional investors own 22.40% of the company’s shares. The stock has risen by 4.93% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the NTEC stock heading into the next quarter.